Pharmaceutical products

Tender description

NHS National Pharmaceuticals Transition 2020_2 Offer reference number: CM/PHG/20/5618 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months). Potential periods of call-offs under the framework agreement. Transition products: — LSNE 1 December 2020 to 30 September 2021 (10 months), — NWLN 1 December 2020 to 31 January 2022 (14 months), — CESW 1 December 2020 to 30 June 2022 (19 months). Hospital only products: All regions 1 December 2020 to 31 January 2022 (14 months). Products on the framework include (but are not limited to): — Ambrisentan — Deferiprone — Fosaprepitant — Micafungin — Noradrenaline (RTU presentations only) — Oseltamivir — Oxycodone/Naloxone (combination) — Prasugrel — Solifenacin — Temsirolimus — Thalidomide — Tipranavir — Tolvaptan — Co-Amoxiclav — Valganciclovir — Valaciclovir — Piperacillin/Tazobactam Pdr for Inj Vial 4 g/500 mg. NHS National Pharmaceuticals Transition 2020_2. Offer reference number: CM/PHG/20/5618 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months). Potential periods of call-offs under the framework agreement. Transition products: — LSNE 1 December 2020 to 30 September 2021 (10 months), — NWLN 1 December 2020 to 31 January 2022 (14 months), — CESW 1 December 2020 to 30 June 2022 (19 months). Hospital only products: All regions 1 December 2020 to 31 January 2022 (14 months). NHS National Pharmaceuticals Transition 2020_2. Offer reference number: CM/PHG/20/5618 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months). Potential periods of call-offs under the framework agreement. Transition products: — LSNE 1 December 2020 to 30 September 2021 (10 months), — NWLN 1 December 2020 to 31 January 2022 (14 months), — CESW 1 December 2020 to 30 June 2022 (19 months). Hospital only products: All regions 1 December 2020 to 31 January 2022 (14 months). NHS National Pharmaceuticals Transition 2020_2. Offer reference number: CM/PHG/20/5618 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months). Potential periods of call-offs under the framework agreement. Transition products: — LSNE 1 December 2020 to 30 September 2021 (10 months), — NWLN 1 December 2020 to 31 January 2022 (14 months), — CESW 1 December 2020 to 30 June 2022 (19 months). Hospital only products: All regions 1 December 2020 to 31 January 2022 (14 months). NHS National Pharmaceuticals Transition 2020_2. Offer reference number: CM/PHG/20/5618 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months). Potential periods of call-offs under the framework agreement. Transition products: — LSNE 1 December 2020 to 30 September 2021 (10 months), — NWLN 1 December 2020 to 31 January 2022 (14 months), — CESW 1 December 2020 to 30 June 2022 (19 months). Hospital only products: All regions 1 December 2020 to 31 January 2022 (14 months).